SUBSIDIARIES

Qilu Pharmaceutical, created in 1958, is located in Jinan, province of Shandong (China) and has eight manufacturing sites for chemical synthesis, genetic-engineering, fermentation, etc. with global presence in North America, Europe, Latin America, Asia, Africa and the Middle East.

The brand value of Qilu has been built on the basis of high quality products and high standard services, ranging from research and development, manufacture of APIs and finished dosage forms, packaging and global commercialization.

SUBSIDIARIES

Qilu Pharmaceutical (Hainan) Co., Ltd.

Founded in 2006, it specializes in the manufacture of lyophilized powder for injection of oncological products. It has a surface area of 87,000 m² and investment levels of around 86 million euros.

Qilu Pharmaceutical (Neimenggu) Co., Ltd.

Founded in 2009 and located in Inner Mongolia, with a surface area of around 400,000 m² it has 1,600 employees and makes antibiotics on a large scale. It is also the biggest producer of avermeticin in the world. It has a level of investment amounting to 171 million euros and a production capacity of 17,000 tons.

Qilu King-phar Pharmaceutical Co., Ltd.

Founded in 1987. This site covers a surface area of 250,000m² and produces over 16,000 tons of antibiotic active ingredients. It produces animal health products and insecticides and over 60% of its products are exported.

Qilu Tianhe Pharmaceutical Co., Ltd.

Founded in 1997 with a surface area of 280,000m², Qilu Tianhe is equipped with the biggest manufacturing facilities of amikacin and tazobactam in the world. It also is the biggest plant with the most advanced technology for the production of sterile lyophilization, and chemical synthesis of oncology products in China. Plant approved for good manufacturing practices by the main regulatory agencies such as FDA (US Food and Drug Administration), MHRA (Medicine and Healthcare products Regulatory Administration United Kindom), TGA (Therapeutic Goods Admnistration of Australia), PMDA (Pharmaceuticals and Medical Devices Agency Japan), EDQM (European Directorate for the Quality of Medicines) y GMP Alemania (Good Manufacturing Practice Germany).

Qilu Antibiotics Pharmaceutical (Jinan) Co., Ltd.

Founded in 1995, it is specialized in the production of Cephalosporin API, and the annual capacity is 1,500 tons. An R&D department was established in 2000.

Qilu Antibiotics Pharmaceutical (Linyi) Co., Ltd.

Founded in 2009, with a total surface area of 334,400m² and more than 800 employees. Its main products are oncological, cardiovascular and cephalosoporin APIs.

Qilu Animal Health Products Co., Ltd.

Founded in 1958, today it has over 1,000 employees. It has 20 different production lines and is dedicated to animal health.

Qilu Synva Pharmaceutica Co., Ltd.

Produces veterinary drugs in bulk, and was founded in May, 2009. It has a surface area of over 32,000m² and investment levels of over 25 million euros.

Qilu Biotechnology Park Co., Ltd.

Qilu Pharmaceutical began the construction of a biotechnology park, the first phase of which is expected to be complete in 2016 with an initial investment of 150 million euros on a surface area of 110,000 m². Manufacturing lines have been established in accordance with the FDA (Food and Drug Administration) / EMA (European Directorate for the Quality of Medicines) for the production of biological medicines.

Qilu Packaging Plant Huanghe.

Qilu Pharmaceutical has state of the art, high performance machinery in order to cover packaging and logistical demands from its 8 subsidiaries.

Qilu Pharma Spain

Qilu Pharma Spain, is the first European subsidiary , established in Spain in late 2014.